Skip to main content
MyDeficiencies

Doxercalciferol

Also sold as Hectorol.

Analyze another medication Medication directory

Findings for this medication

Research about this medication, graded for how strongly each finding can be attributed to it. Nothing here describes your own levels.

Doxercalciferol is a synthetic vitamin D2 prodrug that, unlike the already-active vitamin D receptor (VDR) agonist paricalcitol, requires hepatic activation by the mitochondrial enzyme CYP27 to form its active metabolite, 1α,25-dihydroxyvitamin D2, with a minor pathway forming 1α,24-dihydroxyvitamin D2; renal 1α-hydroxylation is not required, which is the basis for using it in kidney failure. Per its FDA label, mean terminal half-life is approximately 32-37 hours (range up to 96 hours), it is not removed by hemodialysis, and the label does not establish doxercalciferol as a meaningful inducer or inhibitor of host CYP450 enzymes the way it is established for some other vitamin D analogs; the interactions the label documents mostly run in the other direction, with other drugs and cholestyramine altering doxercalciferol's own levels or absorption rather than the reverse.

ATC H05BX03 · also sold as Hectorol (capsule and injection); generic doxercalciferol · reviewed 2026-09-26. This describes research about the medication. It does not say anything about your own levels or health.

How to read the evidence grades

These colours describe how strongly a finding can be attributed to the medication in the research. They are not a severity score and they say nothing about your own health.

Grades describe how strongly a finding can be attributed to Doxercalciferol in the research — not how common it is, how serious it would be, and not anything about you personally.

Red — Severe
severe: ≥2 independent Tier A sources, this drug in the studied cohort, the nutrient/category directly measured, consistent direction, clinically meaningful magnitude, a named plausible mechanism, no substantial contradicting Tier A evidence.
Orange — Moderate
moderate: ≥1 Tier A source with this drug in the cohort showing a real effect, but bounded by exposure window, subgroup, frequency, or a functional rather than confirmed circulating measure.
Yellow — Low
low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where at least one class member has real data but this drug does not; also used for reverse-direction/protective findings and context flags.
Not graded — disclosed evidence gap
Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result.Source definition: evidence gap: no Tier B/C evidence exists to support even a yellow grade, and no circulating consumer claim exists to rebut as white. A disclosed gap in the literature (or in what could be accessed this session), never reworded as reassurance.

What the research found

Calcium

Red — Severe

See study details

Doxercalciferol's labeled VDR-mediated mechanism increases intestinal calcium absorption and can produce hypercalcemia and hypercalciuria; the drug's dose-titration protocol is built explicitly around catching this. This is a retention/excess finding, not a calcium deficiency, and must not be read as one.

Full detail and limits

What the grade means here: severe: ≥2 independent Tier A sources, this drug in the studied cohort, the nutrient/category directly measured, consistent direction, clinically meaningful magnitude, a named plausible mechanism, no substantial contradicting Tier A evidence. RED

Limits on what this shows

  • Key null/negative: None identified — this is an established, expected, and actively monitored effect, not a disputed one. The label does not report separate hypercalcemia incidence rates for the pivotal trials, only the titration protocol built to manage it.
  • At-risk subgroups: Patients also taking calcium-containing phosphate binders or calcium/vitamin D supplements; patients on thiazide diuretics (reduced urinary calcium excretion, additive risk); hepatic impairment (altered activation kinetics complicate titration).
  • Counter-evidence: None on record; direction is not contested in the sources opened this session.

Regulatory status

Labeled warning: doxercalciferol "can cause over suppression of PTH, hypercalcemia, hypercalciuria, hyperphosphatemia, and adynamic bone disease"; hypercalcemia can cause cardiac arrhythmias and seizures and can potentiate digitalis toxicity.

Population evidence

Two placebo-controlled, double-blind 24-week Stage 3-4 CKD studies (doxercalciferol n=27 vs placebo n=28): mean intact PTH decrease of 101 pg/mL vs 4 pg/mL with placebo, 74% of the 27 treated subjects achieving ≥30% PTH suppression. Two double-blind, placebo-controlled dialysis studies in 138 hemodialysis patients (8-week washout, 16-week open-label, 8-week double-blind): 77% achieved intact PTH ≤300 pg/mL. Dosing is explicitly titrated by serum calcium/iPTH: dose reduced if "serum calcium is consistently above the normal range" or iPTH is "persistently and abnormally low," restarted after one week at a dose at least 0.5 mcg (CKD 3-4) or 2.5 mcg (dialysis) lower.

Mechanism

Genomic VDR activation, following hepatic bioactivation to 1α,25-dihydroxyvitamin D2, upregulates intestinal and renal calcium transport machinery.

Counter-evidence held on record

This is an excess/retention risk, not a deficiency. Never use this entry to justify calcium or vitamin D supplementation. The labeled response to rising calcium is dose reduction or withholding doxercalciferol under prescriber guidance, monitored on the schedule in the Monitoring panel below.

Phosphorus

Red — Severe

See study details

Doxercalciferol's VDR-mediated increase in intestinal phosphate absorption compounds chronic kidney disease's own phosphate retention, producing labeled hyperphosphatemia risk. This is a retention/excess finding, not a phosphorus deficiency.

Full detail and limits

What the grade means here: severe: ≥2 independent Tier A sources, this drug in the studied cohort, the nutrient/category directly measured, consistent direction, clinically meaningful magnitude, a named plausible mechanism, no substantial contradicting Tier A evidence. RED

Limits on what this shows

  • Confounding by indication: Hyperphosphatemia is near-universal in CKD from the underlying disease itself. Doxercalciferol's genomic effect on intestinal absorption adds to, rather than causes outright, disease-driven phosphate retention; stated explicitly to avoid overstating attribution.
  • Key null/negative: None identified specific to doxercalciferol; direction is not contested.
  • At-risk subgroups: Patients on calcium/phosphate-containing binders or with poor dietary phosphate-restriction adherence.

Regulatory status

Hyperphosphatemia is named alongside hypercalcemia and adynamic bone disease in the label's over-suppression warning; serum phosphorus is monitored on the same schedule as calcium and intact PTH.

Population evidence

Same pivotal trial pair as the Calcium entry (two 24-week Stage 3-4 CKD RCTs, n=27/28; two dialysis RCTs, 138 patients); phosphorus is tracked as a co-primary safety parameter throughout the titration protocol.

Mechanism

VDR-mediated increase in intestinal phosphate absorption, additive to, not the sole cause of, CKD's own renal phosphate-excretion failure.

Counter-evidence held on record

Excess/retention risk. Never a rationale for phosphate supplementation. Managed by dose titration and dietary/binder strategy under a prescriber, per the label's monitoring schedule.

Magnesium

Orange — Moderate

See study details

Doxercalciferol's label specifically warns against magnesium-containing products (e.g., antacids) in dialysis patients because of hypermagnesemia risk. This reflects impaired renal magnesium clearance in end-stage renal disease, not a doxercalciferol-specific mechanism that removes or wastes magnesium.

Full detail and limits

What the grade means here: moderate: ≥1 Tier A source with this drug in the cohort showing a real effect, but bounded by exposure window, subgroup, frequency, or a functional rather than confirmed circulating measure. ORANGE

Limits on what this shows

  • Key null/negative: None identified; direction is not contested.
  • At-risk subgroups: Hemodialysis and peritoneal dialysis patients using magnesium-containing antacids, laxatives, or phosphate binders.

Regulatory status

Labeled interaction: avoid magnesium-containing products in dialysis patients concomitantly receiving doxercalciferol, due to hypermagnesemia risk.

Population evidence

Tier A label-level warning, bounded specifically to dialysis patients; the label does not extend this warning to the Stage 3-4, non-dialysis CKD population, where renal magnesium handling is comparatively better preserved.

Mechanism

End-stage renal disease reduces renal magnesium excretion. Doxercalciferol does not itself lower or fail to clear magnesium; rather, by treating secondary hyperparathyroidism it does nothing to offset the kidney's impaired magnesium clearance, so any concurrent magnesium load (dietary, antacid, or magnesium-containing phosphate binder) can accumulate. The interaction is additive/permissive, not a direct doxercalciferol-driven retention mechanism of its own.

Why not RED

A single labeled warning without a quantified trial-level incidence figure attached to it in the sections of the label opened this session; strictly bounded to dialysis patients using concurrent magnesium-containing products.

Counter-evidence held on record

This is an excess/retention risk, not a magnesium deficiency. Never use this entry to justify magnesium supplementation. The labeled response is avoidance of magnesium-containing products in this population, with monitoring per the panel below, under a prescriber's guidance.

The five body-system areas

Each finding is counted once, in a single area. Where a study is mentioned in a second area it is context only.

Mitochondrial Burden

Each finding below is counted once, in this area only.

Mitochondrial burden

Yellow — Low

See study details

Unlike already-bioactive VDR agonists, doxercalciferol is a prodrug that specifically requires hepatic mitochondrial CYP27-mediated hydroxylation to become active. This establishes a real, labeled mitochondrial dependency in the drug's own metabolism, but no evidence of adverse mitochondrial burden (structural damage, impaired biogenesis, or dysfunction) attributable to doxercalciferol was found for this drug specifically.

Full detail and limits

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where at least one class member has real data but this drug does not; also used for reverse-direction/protective findings and context flags. YELLOW

Limits on what this shows

  • Key null/negative: None identified; this entry records the absence of burden evidence, not the presence of harm.

Regulatory status

Labeled mechanism of hepatic activation via mitochondrial CYP27 (Tier A, drug-specific).

Population evidence

None identifying doxercalciferol-induced mitochondrial damage in humans or animals was found this session. Two doxercalciferol-specific animal studies, previously inaccessible, were opened this session: Wang XX et al 2011 (renal lipid metabolism in a diet-induced obesity model) reports renal oxidative-stress markers, now cited under the Oxidative stress entry, but no mitochondrial structure, membrane-integrity, or biogenesis data; Zhang Y et al 2009 (diabetic nephropathy model) addresses renin-angiotensin suppression only and does not mention mitochondrial function at all. Neither bears on mitochondrial burden directly. A class-level (not doxercalciferol-specific) lead, Chen H et al 2024, found that calcitriol/paricalcitol VDR activation increases the mitochondrial fusion protein Mfn2 in a diabetic renal tubular model, protecting mitochondrial network integrity under high-glucose stress; see the ATP production entry for the full citation and the Overlap map for how the two entries relate.

Mechanism

Mitochondrial CYP27 hydroxylation is a normal, shared step in vitamin D2/D3 activation generally, not a described toxic or burden-inducing mechanism; the label does not describe a dose-dependent mitochondrial-injury pathway.

Why not ungraded

The mitochondrial-dependency mechanism itself is a real, Tier A, drug-specific fact, not an absence of evidence, which satisfies the yellow bar for a context flag even though no drug-specific burden was found; the class-level Mfn2 finding adds a mechanistically consistent, though not drug-specific, protective signal in the same direction.

Overlap

Shares its underlying source with the Metabolism fact in Pharmacokinetic basis above, and shares its Mfn2/mitochondrial-dynamics mechanism with the ATP production entry via the class-level Chen 2024 study — see Overlap map.

Counter-evidence held on record

This is a metabolic-dependency context flag, not a finding that doxercalciferol damages mitochondria. It should not be read as a caution against the drug, and it does not support a mitochondrial-support supplement claim.

Oxidative Stress

Each finding below is counted once, in this area only.

Oxidative stress

Yellow — Low

See study details

In a doxercalciferol-specific animal study, treatment decreased renal NADPH oxidase subunit expression and oxidized-protein abundance in a diet-induced obesity/renal-disease mouse model. This is a protective, reverse-direction finding, not evidence that doxercalciferol depletes antioxidant capacity.

Full detail and limits

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where at least one class member has real data but this drug does not; also used for reverse-direction/protective findings and context flags. YELLOW

Limits on what this shows

  • Key null/negative: None identified for doxercalciferol; direction is consistently protective in this study. The companion study, Zhang Y et al 2009, was also opened this session and does not mention oxidative stress at all, so it is not counted toward or against this entry.

Regulatory status

Not labeled; from a doxercalciferol-specific animal study, opened in full text this session.

Population evidence

Wang XX et al, Am J Physiol Renal Physiol. 2011 (PMC3064139). Mice fed a diet inducing obesity and insulin resistance, producing renal proteinuria, mesangial expansion, and activation of oxidative stress alongside proinflammatory and profibrotic pathways; doxercalciferol (1α-hydroxyvitamin D2) treatment decreased renal expression of the NADPH oxidase subunits Nox-4, p47-phox, and Nox-2, and decreased abundance of oxidized proteins in the kidney (measured with an OxyELISA Oxidized Protein Quantitation Kit). No numeric magnitude or p-value for these two specific measures was present in the full-text sections retrieved this session.

Mechanism

VDR activation suppressing NADPH-oxidase-driven reactive oxygen species generation and downstream protein oxidation in the kidney, as part of doxercalciferol's broader anti-inflammatory/antifibrotic renal effect in this diet-induced disease model.

Why not higher than yellow

Single animal study in a diet-induced disease model; no human oxidative-stress marker data (e.g., serum MDA, SOD, GSH) exist for doxercalciferol; the retrieved full-text sections describe direction without a quantified statistic for these two measures.

Overlap

None with other entries in this dossier; this is the sole entry resting on Wang XX et al 2011's oxidative-stress findings.

Counter-evidence held on record

Preclinical, single-study, protective-direction signal only. Not evidence of human oxidative-stress harm from doxercalciferol and not a rationale for antioxidant supplementation.

Copper and Iron Balance

Copper and iron are assessed separately. Nothing here is counted twice.

Iron

Yellow — Low

See study details

A class-level, non-drug-specific study found that vitamin D suppresses the iron-regulatory hormone hepcidin and increases markers of cellular iron export (ferroportin, ferritin) in vitro and in a human pilot dose. This points toward improved iron availability, not depletion; doxercalciferol itself has not been tested.

Full detail, limits and 1 references

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where at least one class member has real data but this drug does not; also used for reverse-direction/protective findings and context flags. YELLOW

Limits on what this shows

  • Key null/negative: None on record for doxercalciferol.

Population evidence

Bacchetta J et al, J Am Soc Nephrol. 2014 (PMID 24204002), opened this session via abstract reconstruction. In cultured human hepatocytes and monocytes, vitamin D treatment reduced hepcidin mRNA expression by approximately 50% while increasing ferroportin and ferritin; vitamin D receptor binding to the hepcidin gene (HAMP) promoter was demonstrated directly. In a pilot study of healthy volunteers given a single 100,000 IU dose of vitamin D, serum 25-hydroxyvitamin D rose from 27±2 to 44±3 ng/mL (p<0.001) and circulating hepcidin fell 34% within 24 hours (p<0.05).

Tier and class-extrapolation label

Tier C. The vitamin D used was a standard bolus dose, not doxercalciferol; doxercalciferol itself is absent from this cohort. Labeled explicitly as class extrapolation.

Mechanism

VDR-mediated transcriptional suppression of HAMP (hepcidin), which normally restricts iron export from enterocytes and macrophages via ferroportin degradation; suppressing hepcidin should increase ferroportin-mediated iron availability.

Why not higher than yellow

Not doxercalciferol-specific; a single-dose human pilot plus in vitro data only; no chronic dosing, no CKD-population data, and no direct serum iron, ferritin, or transferrin-saturation outcome reported for doxercalciferol.

Overlap

None with other entries in this dossier.

Counter-evidence held on record

Reverse-direction, mechanistic signal from a different vitamin D form and a non-CKD population. Not evidence of an iron-deficiency effect from doxercalciferol, and not a rationale for iron supplementation or restriction.

Copper

Not graded — disclosed evidence gap

See study details

No verified evidence at any tier connects doxercalciferol, or vitamin D receptor activation generally, to copper status, and no circulating consumer claim exists to rebut.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. UNGRADED

Limits on what this shows

  • Why no grade: This update re-ran the search from scratch. Drug-specific: PubMed listing searches for "doxercalciferol AND copper" and "1alpha-hydroxyvitamin D2 AND copper" both returned zero results this session. Class-level: "vitamin D receptor agonist AND copper" and "calcitriol AND copper AND ceruloplasmin" both returned zero results; a broader search, "vitamin D AND copper AND hemodialysis," returned three results, all incidental multi-element panels or unrelated conditions (bone trace-element content, corneal calcification, dietary intake biomarkers) rather than a mechanistic vitamin-D-copper link. One review-article title surfaced in a further PubMed listing search, "Metal ion homeostasis with emphasis on zinc and copper: Potential crucial link to explain the non-classical antioxidative properties of vitamin D and melatonin" (2021), but its abstract, authors, journal, and DOI could not be retrieved despite repeated attempts across PubMed's article-level pages, Crossref, Semantic Scholar, and OpenAlex, all of which returned bot-verification challenges or persistent rate-limiting throughout this update. Per protocol, an unopened title is not cited as supporting evidence, so this remains a disclosed gap rather than a yellow grade. No circulating consumer claim regarding doxercalciferol and copper was identified.

Access disclosure

This is disclosed as a combined literature/tooling gap: the drug-specific and most class-level searches returned genuine zero results, but one review-article lead could not be verified due to session-wide rate-limiting across every science-literature API tried. A later revision should re-attempt that title once access is confirmed working.

Gut Microbiome Risk

Each finding below is counted once, in this area only.

Gut microbiome risk

Yellow — Low

See study details

Genetic loss of the vitamin D receptor causes gut dysbiosis and altered intestinal microbiome function in mice. Because doxercalciferol activates, rather than removes, VDR signaling, this class-level mechanistic link argues against a disruption risk and toward a neutral-to-protective direction; doxercalciferol itself has not been tested.

Full detail, limits and 1 references

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where at least one class member has real data but this drug does not; also used for reverse-direction/protective findings and context flags. YELLOW

Limits on what this shows

  • Key null/negative: None on record for doxercalciferol.

Population evidence

Jin D et al, Clin Ther. 2015;37(5):996-1009 (PMID 26046242), "Lack of Vitamin D Receptor Causes Dysbiosis and Changes the Functions of the Murine Intestinal Microbiome." VDR-knockout mouse model. Title, authors, journal, and volume/issue/pages were confirmed this session via OpenAlex and Semantic Scholar metadata. The full abstract text could not be retrieved despite repeated attempts this session (Semantic Scholar's abstract field was elided, OpenAlex's abstract index was null, no PMC copy exists per the NCBI ID-converter, and PubMed's article page and Europe PMC were blocked or rate-limited); the finding used here is limited to what the confirmed title itself states.

Tier and class-extrapolation label

Tier C/mechanistic. A genetic-knockout model, not a drug study, and not doxercalciferol-specific; disclosed as class-level mechanistic plausibility rather than direct evidence.

Mechanism

VDR signaling supports Paneth-cell defensin expression and epithelial barrier integrity; its genetic loss produces dysbiosis. A VDR-activating drug would be expected to act in the opposite direction from this knockout model.

Why yellow, not white or ungraded

A real, titled, peer-reviewed finding exists for the receptor pathway generally, satisfying the tightened yellow bar (a real Tier C study exists and the mechanism is plausible for the target drug, even in reverse), so this is not a genuine evidence gap. It is not white because the finding is not a claim to rebut; it is a mechanistic lead pointing away from harm, not a debunked depletion claim.

Overlap

None with other entries in this dossier.

Counter-evidence held on record

A reverse-direction, genetic-model mechanistic lead, not human or drug-specific evidence. It does not support a probiotic or microbiome-support claim, and it does not establish that doxercalciferol itself affects the gut microbiome in either direction.

Oxygen and ATP Output

Oxygen delivery and ATP production are assessed separately. Nothing here is counted twice.

Oxygen delivery/utilization

Orange — Moderate

See study details

In the pivotal placebo-controlled Stage 3-4 CKD trials, anemia was reported in 19% of doxercalciferol-treated patients versus 4% of placebo (n=27 vs n=28, 24 weeks). This is a real but small, unreplicated safety signal reported as an adverse-event term, not a measured hemoglobin trajectory or iron-status finding.

Full detail and limits

What the grade means here: moderate: ≥1 Tier A source with this drug in the cohort showing a real effect, but bounded by exposure window, subgroup, frequency, or a functional rather than confirmed circulating measure. ORANGE

Limits on what this shows

  • Key null/negative: The dialysis-population pivotal trials (138 patients, adverse reactions reported at the ≥2% differential threshold) did not list anemia among the reported adverse reactions, arguing against a strong, generalizable drug effect across the full labeled population.
  • Confounding by indication: Anemia of CKD is extremely common and progresses with declining kidney function. The trial's randomized, placebo-controlled design bounds, but at this sample size does not eliminate, the possibility that faster-progressing disease was unevenly distributed between the two small arms.

Regulatory status

Labeled adverse-reaction table for Stage 3-4 CKD (incidence ≥5%); not framed by the label as a mechanistic or dose-related effect.

Population evidence

Two placebo-controlled, double-blind 24-week studies, doxercalciferol n=27 vs placebo n=28: anemia reported in 19% vs 4%. No hemoglobin delta, hematocrit trajectory, or iron-parameter data were present in the label sections opened this session; this is an adverse-event-term incidence rate, not a quantified hemoglobin change with a confidence interval.

Mechanism

Not established by the label. PubMed searches combining doxercalciferol (and the synonym "1alpha-hydroxyvitamin D2") with hemoglobin, anemia, erythropoietin, and "erythropoietin resistance," across multiple phrasings, returned zero drug-specific studies addressing a mechanism.

Why not RED

A single small trial pair (n=55 total), adverse-event-term granularity rather than a quantified hemoglobin change, and no corroborating signal in the larger dialysis-population trials.

Counter-evidence held on record

This is a labeled adverse-event incidence difference, not a measured iron-deficiency or hemoglobin-mechanism finding. It does not imply an iron or B12 deficiency and carries no supplement implication. Any anemia occurring on doxercalciferol should be evaluated by the prescribing clinician per usual CKD-anemia protocols, not attributed to this entry alone.

ATP production

Yellow — Low

See study details

In a diabetic renal tubular injury model, VDR activation by calcitriol (in vivo) and paricalcitol (in vitro) increased mitochondrial ATP levels and Complex V activity via an Mfn2-dependent pathway, reversing high-glucose-induced ATP reduction. Doxercalciferol was not tested, but the shared VDR-agonist mechanism and matching CKD-relevant tissue make this the most directly relevant class-level lead found.

Full detail, limits and 1 references

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where at least one class member has real data but this drug does not; also used for reverse-direction/protective findings and context flags. YELLOW

Limits on what this shows

  • Key null/negative: None on record for doxercalciferol; the high-glucose/TGF-β control arm itself demonstrates ATP reduction absent VDR activation, included here for mechanistic context, not as contradicting evidence.

Population evidence

Chen H et al, Redox Biology. 2024 (PMID 38320454, DOI 10.1016/j.redox.2024.103062), opened via full text this session. In vivo: 18 diabetic rats (6/group) treated with calcitriol for 24 weeks. In vitro: HK-2 human renal tubular cells exposed to high glucose/TGF-β plus 200 nM paricalcitol, with VDR overexpression/siRNA and Mfn2 siRNA used to test dependence. High glucose/TGF-β significantly reduced mitochondrial ATP; paricalcitol treatment reversed this reduction (p<0.05); Mfn2 siRNA partially abolished the paricalcitol-driven increase in mitochondrial ATP and Complex V activity, confirming Mfn2-dependence.

Tier and class-extrapolation label

Tier C. Calcitriol and paricalcitol were used, not doxercalciferol; doxercalciferol is absent from this cohort. Labeled as class extrapolation. The tissue (renal tubular cells under diabetic/high-glucose injury) is directly analogous to doxercalciferol's own CKD indication, which strengthens plausibility relative to an unrelated-tissue class lead.

Mechanism

VDR activation upregulates Mfn2 (a mitochondrial fusion protein), preserving mitochondrial network integrity and oxidative ATP-generating capacity under metabolic stress.

Why not higher than yellow

Not doxercalciferol-specific; animal and cell-culture only; no human ATP or renal-tubular bioenergetic data exist for any vitamin D analog, including doxercalciferol.

Overlap

Shares its Mfn2/mitochondrial-dynamics mechanism with the Mitochondrial burden entry above — see Overlap map. Do not read these as two independent confirmations.

Counter-evidence held on record

Preclinical, protective-direction, class-extrapolated signal only. Not human or doxercalciferol-specific ATP data, and not a rationale for any energy or mitochondrial-support supplement claim.

Claims checked and not supported

These circulate online for this medication. They are listed here only so they can be answered, never as findings, and they are not graded.

A claim with no supporting evidence is not necessarily disproven. Where evidence actually argues against a claim, that is stated below.

  • "Doxercalciferol depletes magnesium"

    Where it comes from: General vitamin-D-analog depletion-claim genre, applied to this drug by extension.

    Why it fails: Doxercalciferol's own FDA label states the opposite direction: a hypermagnesemia (excess) risk in dialysis patients using concurrent magnesium-containing products, driven by impaired renal magnesium clearance in end-stage renal disease, not a doxercalciferol-driven loss. No mechanism in the Step 2 screen (absorption interference, renal wasting, cofactor antagonism, or increased utilization) supports a depletion direction for this drug.

  • "Active vitamin D analogs (including doxercalciferol) deplete vitamin K2"

    Where it comes from: Common wellness/naturopathic claim about vitamin D compounds generally, based on the idea that vitamin K2 is "used up" directing calcium into bone.

    Why it fails: No mechanism is identified in the label (no vitamin K absorption interference, catabolism-acceleration, or increased-utilization pathway is named for doxercalciferol), and no doxercalciferol-specific or class-level primary study was found this session supporting a consumptive relationship between vitamin D activation and vitamin K status. The literature on vitamin D and K2 that does exist describes a complementary role in calcium/vascular biology, not a depletion mechanism.

  • "Doxercalciferol depletes the body's own (natural) vitamin D"

    Where it comes from: Consumer confusion between a synthetic vitamin D analog drug and endogenous vitamin D status.

    Why it fails: Doxercalciferol is itself an exogenous vitamin D2 prodrug, given specifically to bypass the kidney's own impaired 1α-hydroxylation step in CKD. It does not consume, catabolize, or displace endogenous 25-hydroxyvitamin D3, and no mechanism or evidence was found for such an effect.

All references used above
  1. FDA Prescribing Information, Doxercalciferol Capsules. — DailyMed (Heritage Pharmaceuticals), setid 2ed2f592-27a7-4c10-a18a-21a3f221d3b1. Sections opened: mechanism of action, clinical pharmacology, drug interactions, dosing and administration, adverse reactions, use in specific populations.
  2. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index, code H05BX (Other anti-parathyroid agents). — Confirms doxercalciferol as H05BX03, alongside cinacalcet (H05BX01), paricalcitol (H05BX02), etelcalcetide (H05BX04), calcifediol (H05BX05), evocalcet (H05BX06).
  3. Wang XX, Jiang T, Shen Y, Santamaria H, Solis N, Arbeeny C, Levi M. Vitamin D receptor agonist doxercalciferol modulates dietary fat-induced renal disease and renal lipid metabolism. — Am J Physiol Renal Physiol. 2011. PMC3064139. DOI 10.1152/ajprenal.00338.2010. Doxercalciferol-specific animal study; supports the Oxidative stress entry (yellow).Blocked in the original review; opened in full text this update via PubMed Central (PMC3064139).
  4. Zhang Y, Deb DK, Kong J, Ning G, Wang Y, Li G, Chen Y, Zhang Z, Strugnell S, Sabbagh Y, Arbeeny C, Li YC. Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist. — Am J Physiol Renal Physiol. 2009. PMID 19535571. DOI 10.1152/ajprenal.00247.2009. Doxercalciferol-specific animal study; addresses renin-angiotensin suppression only, no mention of oxidative stress, mitochondria, ATP, copper, or iron. Not used to support any of the five categories in this update.Blocked in the original review; opened in full text (abstract-level) this update via OpenAlex.
  5. Bacchetta J, Zaritsky JJ, Sea JL, Chun RF, Lisse TS, Zavala K, Nayak A, Wesseling-Perry K, Westerman M, Hollis BW, Salusky IB, Hewison M. Suppression of iron-regulatory hepcidin by vitamin D. — J Am Soc Nephrol. 2014. PMID 24204002. DOI 10.1681/ASN.2013040355. Class-level (vitamin D generally; not doxercalciferol-specific). Supports the Iron entry (yellow).Blocked in the original review; abstract reconstructed this update via OpenAlex.
  6. Jin D, Wu S, Zhang YG, Lu R, Xia Y, Dong H, Sun J. Lack of Vitamin D Receptor Causes Dysbiosis and Changes the Functions of the Murine Intestinal Microbiome. — Clin Ther. 2015;37(5):996-1009. PMID 26046242. DOI 10.1016/j.clinthera.2015.04.004. Class-level, VDR-knockout mouse model; not doxercalciferol-specific. Supports the Gut microbiome risk entry (yellow), cited at the confirmed-title level only.Title, authors, and journal metadata confirmed this update via OpenAlex and Semantic Scholar. The full abstract still could not be retrieved (elided by Semantic Scholar, null in OpenAlex, no PMC copy exists, and PubMed/Europe PMC access was blocked or rate-limited throughout this update); the entry above cites only what the confirmed title states.
  7. Chen H, Zhang H, Li AM, Liu YT, Liu Y, Zhang W, Yang C, Song N, Zhan M, Yang S. VDR regulates mitochondrial function as a protective mechanism against renal tubular cell injury in diabetic rats. — Redox Biology. 2024. PMID 38320454. DOI 10.1016/j.redox.2024.103062. Class-level (calcitriol in vivo, paricalcitol in vitro; not doxercalciferol-specific). Supports the ATP production entry (yellow) and the Mitochondrial burden entry's class-level Mfn2 note.Newly identified and opened this update, via PubMed listing search, Crossref, Unpaywall, and full text at ScienceDirect.
  8. "Metal ion homeostasis with emphasis on zinc and copper: Potential crucial link to explain the non-classical antioxidative properties of vitamin D and melatonin" (title as returned by a PubMed listing search this update; authors not confirmed). — Approximately 2021, per the listing snippet. Class-level review; not doxercalciferol-specific.Newly surfaced this update as a possible lead for Copper. Title only; PMID, DOI, authors, and abstract could not be retrieved despite repeated attempts across PubMed's article-level pages, Crossref, Semantic Scholar, and OpenAlex, all blocked by bot-verification or rate-limiting during this update. Not cited as supporting evidence per protocol; disclosed only as an unverified lead for a later revision under the Copper entry.
  9. Frazao JM, Chesney RW, Coburn JW. Intermittent oral 1alpha-hydroxyvitamin D2 is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients. — 1998. PMID 9568825.Title and authors confirmed via PubMed listing search only; abstract not opened this session. Excluded from grading; listed for completeness as an early doxercalciferol dialysis trial.
  10. Yang G, Huang Y, Ge Y, Yu X, Liu L, et al. Efficacy and safety of intermittent intravenous doxercalciferol in the treatment of secondary hyperparathyroidism in Chinese patients on maintenance hemodialysis: a phase II, open-label, prospective, multicenter study. — Front Pharmacol. 2025. PMID 40290446. DOI 10.3389/fphar.2025.1574679.Title and authors confirmed via Europe PMC bibliographic listing only; abstract not opened this session. Excluded from grading; listed for completeness.
  11. Zisman AL, Ghantous W, Schinleber P, Roberts L, Sprague SM. Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol. — 2005. PMID 16282676.Title and authors confirmed via PubMed listing search only; abstract not opened this session. Excluded from grading; listed for completeness re: class dose-equivalency.
  12. Palmer SC, McGregor DO, Craig JC, Elder G, Macaskill P, Strippoli GF. Vitamin D compounds for people with chronic kidney disease requiring dialysis. — Cochrane Database Syst Rev. 2009. PMID 19821349.Title confirmed via PubMed listing search only; abstract not opened this session. Excluded from grading; listed for completeness as a class-level Cochrane review stratifying by compound, including doxercalciferol.
  13. Palmer SC, McGregor DO, Craig JC, Elder G, Macaskill P, Strippoli GF. Vitamin D compounds for people with chronic kidney disease not requiring dialysis. — Cochrane Database Syst Rev. 2009. PMID 19821446.Same disclosure as above. Excluded from grading; listed for completeness.